患有加速期或急变期骨髓增殖性肿瘤的患者预后不佳。德卡斯特罗等人的报告。提供了关于将干扰素 α2 与 5-氮杂胞苷和 JAK1-2 抑制剂（鲁索替尼）相结合的新型治疗方法的基本原理和前景的重要信息，该方法将在精心设计的临床试验中进行探索。评论：卡斯特罗等人。干性与干扰素信号传导的比率作为骨髓增生性肿瘤进展为急性髓性白血病的生物标志物和治疗靶点。 Br J Haematol 2023（印刷前在线）。 doi: 10.1111/bjh.19107.© 2023 作者。英国血液学杂志由英国血液学会和约翰·威利出版

Patients with accelerated or blast phase myeloproliferative neoplasms have a dismal prognosis. The report by de Castro et al. provides important information on the rationale and prospect for a novel therapeutic approach combining interferon-alpha2 with 5-azacytidine and a JAK1-2 inhibitor (ruxolitinib) to be explored in well-designed clinical trials. Commentary on: Castro et al. Ratio of stemness to interferon signalling as a biomarker and therapeutic target of myeloproliferative neoplasm progression to acute myeloid leukaemia. Br J Haematol 2023 (Online ahead of print). doi: 10.1111/bjh.19107.© 2023 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.